On the afternoon of August 12, 2022, an eight-person expert team led by Party Secretary Mr. Jun Yuan and Deputy Director Ms. Lei Yang of the Sichuan Institute for Drug Control visited MAXVAX. Among those were experts from the Institute for Inspection of Biological Products and the Biological Sample Testing Center. Maxvax’s General Manager Dr. Dexiang Chen, quality control team, R&D team, operation management, and key technicians gave the visiting team a warm welcome. The two sides had a meeting, after which the expert team visited our laboratory and pilot workshop.

At the meeting, Mr. Yan Li, Director of the Institute for Inspection of Biological Products, started with an overview on the main work of the Institute under the Sichuan Institute for Drug Control and its scientific research which had been approved as Key Laboratory by National Medical Products Administration (NMPA). Mr. Boping Wei, Director of the Biological Sample Testing Center, gave an account of the Center's work with a specific focus on the clinical trial sample testing.

Next, Dr. Chen outlined the company’s current development, including product programs in the pipeline and core technologies. Ms. Jing Chen, head of quality department, gave a report on the company’s achievements in quality control and research of innovative vaccines.

The two sides shared insights on industry development and cutting-edge R&D in innovative vaccines and reached a consensus and an initial intention for cooperation in R&D technology roadmap and related technologies for vaccine R&D.

Dr. Chen also expressed his hope to further strengthen communication and cooperation with the Sichuan Institute for Drug Control in order to make progress in the company’s R&D pipeline.

Secretary Yuan stressed that the regulatory authorities were taking on heavier responsibilities with the robust development of China's vaccine industry. With the China Vaccine Production and Distribution Rules recently released by NMPA, the Sichuan Institute for Drug Control has started to plan for the lot release of biological products. Meanwhile, he hoped that services and cooperation throughout the life cycle of the R&D stage would be covered in the future to promote the sound development of Sichuan’s innovative vaccine industry.